베라 테라퓨틱스(VERA)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $33.88 (-1.14%), 시가총액 $2.81B, 52주 최저~최고 $18.87 ~ $55.67.
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-in
베라 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
베라 테라퓨틱스의 현재 주가는 $33.88 (-1.14%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
베라 테라퓨틱스의 시가총액은 약 $2.81B입니다.
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company off